Summit Therapeutics (SMMT) Accumulated Depreciation & Amortization (2019 - 2024)
Summit Therapeutics filings provide 6 years of Accumulated Depreciation & Amortization readings, the most recent being $1.1 million for Q4 2024.
- Quarterly Accumulated Depreciation & Amortization rose 7.29% to $1.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2024, up 7.29% year-over-year, with the annual reading at $1.1 million for FY2024, 7.29% up from the prior year.
- Accumulated Depreciation & Amortization hit $1.1 million in Q4 2024 for Summit Therapeutics, up from $1.0 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $1.3 million in Q4 2022 and bottomed at $1.0 million in Q4 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
- The largest annual shift saw Accumulated Depreciation & Amortization soared 2616.62% in 2020 before it decreased 19.66% in 2023.
- Summit Therapeutics' Accumulated Depreciation & Amortization stood at $1.1 million in 2020, then decreased by 8.24% to $1.0 million in 2021, then grew by 25.19% to $1.3 million in 2022, then decreased by 19.66% to $1.0 million in 2023, then increased by 7.29% to $1.1 million in 2024.
- Per Business Quant, the three most recent readings for SMMT's Accumulated Depreciation & Amortization are $1.1 million (Q4 2024), $1.0 million (Q4 2023), and $1.3 million (Q4 2022).